NEW YORK, Feb. 02, 2018 -- TransPerfect Life Sciences, a leading provider of technologies and services to support clinical trials and product development for the biopharmaceutical industry, today announced that ARCA Biopharma has selected TransPerfect’s Trial Interactive eTMF solution as their enterprise platform for clinical trials.
|
|||
ARCA Biopharma is a Colorado-based biopharmaceutical company that focuses on developing genetically targeted therapies for cardiovascular diseases. They initially selected TransPerfect’s Trial Interactive eTMF to support a Phase 2 trial conducted across 50 sites, and will be using the multitenant, cloud-based solution to move all trials to a paperless environment.
The Trial Interactive e-clinical platform was designed by clinical professionals, for clinical professionals. It is used by biopharmaceutical organizations and CROs to streamline product development lifecycles in a secure 21 CFR Part 11-compliant environment. Trial Interactive speeds time to market by moving cumbersome traditional paper-based study start-up and TMF management to the cloud. Stakeholders have real-time access to documentation and transparency into workflows, which drastically reduces travel and shipping requirements associated with review and reconciliation.
“ARCA Biopharma is doing incredible work in the cardiovascular space, and their innovative approach to development is truly ground-breaking,” said Michael Smyth, General Manager, Life Sciences Solutions at TransPerfect. “By moving to a cloud-based solution for TMF management, ARCA is able to optimize trial decisions around key elements like site selection and performance, study start-up, and management of critical study data.”
“Our search for an eTMF solution required that we find a product that met DIA requirements and was designed and backed by people who truly understand the world of clinical trials,” said Eric Negrey, Senior Director of IT and Facilities at ARCA Biopharma. “The claims made by the Trial Interactive team during our evaluation process were proven overwhelmingly true; it’s easy to use, provides us with significant insight into TMF completeness, and reporting on key data is simple and comprehensive. Trial Interactive has without question improved ARCA’s ability to complete trials in the most efficient manner possible.”
About Trial Interactive
TransPerfect’s Trial Interactive solution provides a collaborative, web-based platform for clinical development that enables sponsors, CROs, IRBs, and other vendors to maintain and update clinical trial documentation in a secure online environment, adhering to global regulatory requirements. With fully searchable solutions including investigator portals, Trial Interactive streamlines study timelines and reduces the administrative burdens of global clinical trials. As part of TransPerfect’s Life Sciences division, Trial Interactive is dedicated to working with clients on a global, collaborative level, supporting a wide range of requirements including e-feasibility, study start-up, eTMF review/reconciliation, mobile applications, learning management and document management systems, investigator portals, pharmacovigilance and safety management, and endpoint adjudication. For more information on Trial Interactive, please contact [email protected] or +1 212.400.8848, or visit www.trialinteractive.com.
About TransPerfect
TransPerfect is the world’s largest provider of language services and technology solutions for global business. From offices in over 90 cities on six continents, TransPerfect offers a full range of services in 170+ languages to clients worldwide. More than 4,000 global organizations employ TransPerfect’s GlobalLink® Product Suite to simplify management of multilingual content. With an unparalleled commitment to quality and client service, TransPerfect is fully ISO 9001 and ISO 17100 certified. TransPerfect has global headquarters in New York, with regional headquarters in London and Hong Kong. For more information, please visit our website at www.transperfect.com.
Contact:
Ryan Simper +1 212.689.5555
[email protected]


Samsung Electronics Shares Jump on HBM4 Mass Production Report
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 



